×
About 2,803 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  1,111 results

Clinical and histopathological features of myeloid neoplasms with concurrent Janus kina...
https://doi.org/10.1111/bjh.17567
British Journal of Haematology; Naumann N, Lübke J et. al.

Jun 1st, 2021 - We report on 45 patients with myeloid neoplasms and concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V (JAK2pos . /KITpos . ) mutations, which are individually identified in >60% of patients with cl...

Divergent PGD2 and leukotriene C4 metabolite excretion following aspirin therapy: Ten p...
https://doi.org/10.1016/j.prostaglandins.2021.106563
Prostaglandins & Other Lipid Mediators; Butterfield JH, Singh RJ

May 24th, 2021 - Aspirin-exacerbated respiratory disease and some cases of chronic idiopathic urticaria are disorders in which increased baseline urinary excretion of leukotriene(LT)E4 further increases following aspirin administration. Increased urinary excretion...

Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (...
https://doi.org/10.1016/j.leukres.2021.106606
Leukemia Research; Taylor F, Li X et. al.

May 18th, 2021 - The Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) was developed to evaluate symptoms of advanced systemic mastocytosis (AdvSM). This study aimed to psychometrically evaluate AdvSM-SAF scores and provide score interpretation gu...

GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastoc...
https://doi.org/10.1182/blood.2020008948
Blood Agopian J, Da Costa Q et. al.

May 11th, 2021 - Systemic mastocytosis (SM) is a KIT-driven hematopoietic neoplasm characterized by the excessive accumulation of neoplastic mast cells (MCs) in various organs and, mainly, the bone marrow (BM). Multiple genetic and epigenetic mechanisms contribute...

Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis.
https://doi.org/10.1007/s11882-021-01010-1 10.1016/j.aller.2014.05.002 10.1111/all.12317 10.1159/000497235 10.1046/j.1365-2222.2003.01755.x 10.1016/j.jaci.2009.08.027 10.1111/ajd.12146 10.1111/j.1398-9995.2007.01569.x 10.1111/cea.12225 10.1056/NEJMra1409760 10.1067/mai.2002.121454 10.1172/JCI118337 10.4049/jimmunol.170.11.5667 10.1016/s0091-6749(99)70184-3 10.1016/j.clim.2007.02.007 10.1016/j.iac.2006.05.010 10.1515/CCLM.2010.124 10.1182/blood-2016-09-731893 10.1586/17474086.2014.955008 10.1016/j.jaci.2013.11.039 10.1038/ng.3696 10.1016/j.jaci.2014.06.007 10.1038/gim.2017.136 10.1016/j.iac.2018.04.003 10.1016/j.jaip.2016.11.037 10.1016/j.jaci.2005.12.1303 10.2500/aap.2019.40.4211 10.4168/aair.2014.6.4.304 10.1186/s12948-015-0017-9 10.1182/blood-2006-06-028100 10.1016/j.jaci.2017.05.036 10.1016/j.iac.2014.01.003 10.1007/s10875-018-0506-y 10.1038/nri3690 10.1016/0076-6879(94)44008-5 10.1016/j.jaci.2006.02.026 10.1084/jem.20190701 10.1056/NEJMoa1500611 10.3349/ymj.2010.51.6.808 10.1074/jbc.273.50.33224 10.1007/978-1-4684-5143-6_15 10.4049/jimmunol.180.9.6307 10.1016/j.cell.2019.09.009 10.4049/jimmunol.179.9.6072 10.1016/j.jaip.2020.05.057 10.1016/j.jaip.2019.02.002 10.1016/j.jaip.2017.11.025 10.1016/j.anai.2019.09.026 10.1159/000501637 10.1016/j.iac.2020.06.007
Current Allergy and Asthma Reports; Wu R, Lyons JJ

May 10th, 2021 - Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait and a common cause of elevated basal serum tryptase in Western populations. It is a risk factor for severe anaphylaxis among individuals with venom allergy and an establishe...

see more →

Guidelines  2 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

see more →

Drugs  251 results see all →

Clinicaltrials.gov  1,397 results

Clinical and histopathological features of myeloid neoplasms with concurrent Janus kina...
https://doi.org/10.1111/bjh.17567
British Journal of Haematology; Naumann N, Lübke J et. al.

Jun 1st, 2021 - We report on 45 patients with myeloid neoplasms and concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V (JAK2pos . /KITpos . ) mutations, which are individually identified in >60% of patients with cl...

Divergent PGD2 and leukotriene C4 metabolite excretion following aspirin therapy: Ten p...
https://doi.org/10.1016/j.prostaglandins.2021.106563
Prostaglandins & Other Lipid Mediators; Butterfield JH, Singh RJ

May 24th, 2021 - Aspirin-exacerbated respiratory disease and some cases of chronic idiopathic urticaria are disorders in which increased baseline urinary excretion of leukotriene(LT)E4 further increases following aspirin administration. Increased urinary excretion...

Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (...
https://doi.org/10.1016/j.leukres.2021.106606
Leukemia Research; Taylor F, Li X et. al.

May 18th, 2021 - The Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) was developed to evaluate symptoms of advanced systemic mastocytosis (AdvSM). This study aimed to psychometrically evaluate AdvSM-SAF scores and provide score interpretation gu...

GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastoc...
https://doi.org/10.1182/blood.2020008948
Blood Agopian J, Da Costa Q et. al.

May 11th, 2021 - Systemic mastocytosis (SM) is a KIT-driven hematopoietic neoplasm characterized by the excessive accumulation of neoplastic mast cells (MCs) in various organs and, mainly, the bone marrow (BM). Multiple genetic and epigenetic mechanisms contribute...

Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis.
https://doi.org/10.1007/s11882-021-01010-1 10.1016/j.aller.2014.05.002 10.1111/all.12317 10.1159/000497235 10.1046/j.1365-2222.2003.01755.x 10.1016/j.jaci.2009.08.027 10.1111/ajd.12146 10.1111/j.1398-9995.2007.01569.x 10.1111/cea.12225 10.1056/NEJMra1409760 10.1067/mai.2002.121454 10.1172/JCI118337 10.4049/jimmunol.170.11.5667 10.1016/s0091-6749(99)70184-3 10.1016/j.clim.2007.02.007 10.1016/j.iac.2006.05.010 10.1515/CCLM.2010.124 10.1182/blood-2016-09-731893 10.1586/17474086.2014.955008 10.1016/j.jaci.2013.11.039 10.1038/ng.3696 10.1016/j.jaci.2014.06.007 10.1038/gim.2017.136 10.1016/j.iac.2018.04.003 10.1016/j.jaip.2016.11.037 10.1016/j.jaci.2005.12.1303 10.2500/aap.2019.40.4211 10.4168/aair.2014.6.4.304 10.1186/s12948-015-0017-9 10.1182/blood-2006-06-028100 10.1016/j.jaci.2017.05.036 10.1016/j.iac.2014.01.003 10.1007/s10875-018-0506-y 10.1038/nri3690 10.1016/0076-6879(94)44008-5 10.1016/j.jaci.2006.02.026 10.1084/jem.20190701 10.1056/NEJMoa1500611 10.3349/ymj.2010.51.6.808 10.1074/jbc.273.50.33224 10.1007/978-1-4684-5143-6_15 10.4049/jimmunol.180.9.6307 10.1016/j.cell.2019.09.009 10.4049/jimmunol.179.9.6072 10.1016/j.jaip.2020.05.057 10.1016/j.jaip.2019.02.002 10.1016/j.jaip.2017.11.025 10.1016/j.anai.2019.09.026 10.1159/000501637 10.1016/j.iac.2020.06.007
Current Allergy and Asthma Reports; Wu R, Lyons JJ

May 10th, 2021 - Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait and a common cause of elevated basal serum tryptase in Western populations. It is a risk factor for severe anaphylaxis among individuals with venom allergy and an establishe...

see more →

News  37 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Avapritinib yields high response rate in patients with systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/153966/myelodysplastic-syndrome/avapritinib-yields-high-response-rate
Andrew D. Bowser

Dec 10th, 2017 - ATLANTA – An oral investigational drug with specific activity against a mutation frequently found in advanced systemic mastocytosis (ASM) produced clinical responses in the majority treated patients, according to preliminary data presented at the.

see more →

Patient Education  5 results see all →